FBXL5, also previously identified as an onco‐suppressor,[16, 26, 27] exhibits an adverse association with the survival of cancer patients.[28] Downregulation of FBXL5 has been shown to elevate intracellular ROS levels via iron overload, although it was unable to induce ferroptosis.[16] Our observations in NSCLC cells further underscore the dependency of ALKBH5 on FBXL5 to decrease intracellular ROS, thereby inhibiting oncogenic pathways and malignant phenotype. The gene discussed is FBXL5; the disease is cancer.